 |
|
|
| |
Evaluation of Renal and Bone Safety in Post-Liver Transplant Patients With
Chronic Kidney Disease Receiving Tenofovir Alafenamide for HBV Prophylaxis
|
| |
| |
Reported by Jules Levin
EASL 2018 April 11-15 Paris France
Ed Gane,1 Bibin George,1 Stephen Munn,1 Hongyuan Wang,2 Vithika Suri,2 John Flaherty,2 Anuj Gaggar2
1 New Zealand Liver Transplant Unit, Auckland City Hospital, Auckland, New Zealand; 2Gilead Sciences, Inc., Foster City, California, USA
References
1. Lucey MR, et al. Liver Transpl 2013;19:3-26; 2. Ojo AO, et al. N Engl J Med 2003;349:931-40; 3. Maalouf NM, Shane E. J Clin Endocrinol Metab 2005;90:2456-65; 4. Babusis D, et al. Mol Pharmaceutics
2013;10:459-66; 5. Lee WA, et al. Antimicrob Agents Chemother 2005;49:1898-906; 6. Murakami E, et al. Antimicrob Agents Chemother 2015;59:3563-9; 7. Agarwal K, et al. J Hepatol 2015;62:533-40;
8. Agarwal K, et al. J Hepatol 2018;68:672-81; 9. Buti M, et al. Lancet Gastroenterol Hepatol 2016;1:196-206; 10. Chan HLY, et al. Lancet Gastroenterol Hepatol 2016;1:185-95.
|
| |
|
|
|
|
|
